FILING ANALYSIS · TUESDAY, NOVEMBER 10
Autolus Therapeutics plc AUTL — 8-K: Results of Operations and Financial Condition
positive
Autolus Therapeutics reported a 95% year-over-year increase in AUCATZYL net product revenue to $41.2 million and raised its full-year 2026 revenue guidance to at or exceeding $150 million, driven by growing volumes and manufacturing efficiency initiatives.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →